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High WBP5 expression correlates 
with elevation of HoX genes levels 
and is associated with inferior 
survival in patients with acute 
myeloid leukaemia
c. Ward1,2,3, P. cauchy  4, P. Garcia5, J. frampton5, M. A. esteban  1,2,3,6,7 & G. Volpe1,2,3,5*
WW domain binding protein 5 (WBP5), also known as Transcriptional Elongation Factor A like 9 
(TCEAL9) has been proposed as a candidate oncogene for human colorectal cancers with microsatellite 
instability and as a predictive indicator of small cell lung cancers. Furthermore, several independent 
studies have proposed WBP5, and its association with Wilms Tumor-1 (WT1) expression, as part of a 
gene expression-based risk score for predicting survival and clinical outcome in patients with Acute 
Myeloid Leukaemia (AML). To date, the prognostic significance of the sole WBP5 expression and its 
impact on the survival outcome in AML patients remains largely understudied. In the present study, 
we have made use of publicly available patient expression arrays and have developed an unbiased 
approach to classify AML patients into low versus high WBP5 expressers and to balance them for known 
mutations and cytogenetic findings. Interestingly, we found that patients characterized by high WBP5 
expression displayed inferior overall and event-free survival rates. Notably, gene expression profiling 
showed that patients with high WBP5 had elevated expression of several HOX cluster genes, such as 
HOXA5, HOXA7, HOXA9 and HOXA10, and several of their partner proteins, such as MEIS1 and FOXC1, 
which have been demonstrated to be causative for AML. Taken together, our data suggest that WBP5 
expression level could serve as an indicator for prognosis and survival outcome in patients with AML.
Acute myeloid leukaemia (AML) is a hierarchically-organized myeloproliferative disorder that is caused by step-
wise acquisition of different mutations that prime malignant transformation and affect normal maturation of 
myeloid precursor cells1,2. Despite concerted efforts in the development of new treatments, many patients are 
refractory to current therapeutic approaches or have a high relapse rate, with the overall long-term survival of 
patients being below 40% and more than 60% of the patients over 65 years of age succumbing to the disease 
within one year of diagnosis3. In current medical practice, the diagnosis, prognosis, and therapeutic choices are 
dictated by detection of genetic mutations and the measurement of specific biomarkers that are used to classify 
patients into risk categories. However, due to the heterogeneous nature of the disease, prognosis within these 
categories is highly variable.
Aside from chromosome lesions, such as those involving MLL (i.e. MLL-AF9, MLL-ENL)4,5 or RUNX1 (i.e. 
RUNX1-ETO, RUNX1-EVI1)6,7 translocations, common prognostic and categorization factors involve muta-
tions in the genes encoding signalling proteins (FLT3, RAS and KIT)8,9, transcription factors (CEBPA, PU.1 and 
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GATA2)10–12 and DNA methylation related genes (TET2, DNMT3A, IDH1 and IDH2)13–16. Patient stratification 
has been further refined by the advent of next-generation whole-genome and transcriptome sequencing tech-
nologies; however, the identification of new reliable biomarkers is still required in clinical practice for use as 
prognostic factors and as new actionable therapeutic targets.
WW domain binding protein 5 (WBP5), a novel upstream regulator of the Hippo pathway17, has been recently 
associated with a variety of cancers, such as advanced gastric cancer with aggressive lymph node metastasis18, 
colorectal cancers with microsatellite instability19 and in small cell lung cancers20 where it has been reported to 
influence tumour growth by promoting cell proliferation and inhibiting apoptosis. A link of WBP5 with leukaemia 
has become evident in recent years through the generation of gene expression prognostic signatures for predicting 
clinical outcomes in patients with AML. In fact, by making use of cDNA microarrays, Metzeler and co-workers 
presented WBP5 as part of a gene expression-based signature that comprises an 86-probe set (66 genes), 
which was used for predicting survival outcome in patients with cytogenetically normal AML (CN-AML)21. 
Subsequently, Bou Samra et al. developed an independent and further refined gene expression-based risk score 
in which WBP5 was part of a 22-gene signature that displayed a strong prognostic value in 2 independent cohorts 
of CN-AML patients22. Recently, Niavarani et al. have reported WBP5 as part of a 17-probe set signature to 
predict unfavourable outcome in association with high levels of WT1 in AML patients23. To date, whether the 
sole expression of WBP5 could serve as a prognostic indicator and whether its expression has any impact on the 
establishment and maintenance of myeloid diseases has not been assessed.
In the present study, we have taken an unbiased bioinformatic approach to identify new molecular biomarkers 
by making use of publicly available patient gene expression arrays in which the whole AML patient cohort was 
ranked according to the expression of every gene probe into high and low expressers and used to determine the 
impact of this classification on the overall and event-free survival outcome and on the gene expression profiles. 
Our approach identified WBP5 as one of the most significant genes and showed that high expression of WBP5 is 
associated with a markedly inferior outcome and with an elevation of leukaemia associated HOX gene clusters 
expression. The prognostic value of WBP5 was validated in five independent AML gene expression datasets, thus 
suggesting WBP5 to be a new reliable molecular biomarker and a new potential therapeutic candidate for AML 
patients.
Materials and Methods
Patient profiling arrays information. The overall survival (OS) and event-free survival (EFS) scores were 
determined using non-parametric Kaplan-Meyer estimates; comparison of survival between the low and high 
WBP5 subgroups was based on two-sided log rank test.
Data processing. GSE689124, GSE1543425, GSE1320426, GSE115927, GSE2284528 microarray raw data were 
downloaded from NCBI Gene Expression Omnibus (GEO). For each probe in each dataset, expression was scaled 
from 0 to 1. Then high and low expressing patient groups were established using 0.7–1 or 0–0.3 expression, 
respectively. Once subgroups were determined, raw CEL data was downloaded for each patient and expression 
values were calculated, background corrected, log2 transformed and quantile normalized in R (version 3.6.0) 
using affy package (version 1.62.0) and the rma function. Differential gene expression was carried out using the 
limma package (version 3.40.2) by fitting a linear model of high vs low patients for WBP5 expression.
Subgroup balancing. After selecting high and low expressing patients as separate subgroups, we checked if 
there was a significant proportion of each subgroup that contained patients with specific cytogenetic abnormality, 
disease marker expression, age or gender using Fisher exact test. If we found a significant imbalance, we adopted 
a randomization strategy to balance the groups. Patients were shuffled in and out of the high and low expressing 
subgroups until there was no significant proportion of a specific cytogenetic abnormality, disease marker expres-
sion, age or gender.
Survival analysis. For the GSE6891, GSE1241721 and GSE3764229 datasets, the high expressing subgroup 
and the low expressing subgroup were compared for each probe using overall survival data. Event-free survival 
was analysed for GSE6891 dataset only. A p-value was calculated to determine significant differences using 
Wilcoxon rank-sum test.
Kaplan-Meier plots were generated using Python (version 3.5.5) lifelines package (version 0.14.6). P-values 
represent Wilcoxon rank-sum test results comparing high and low expressing patients.
Unsupervised hierarchical clustering. The hierarchical clustering of patients shown in this study was 
unsupervised and was performed on normalized data using Pearson correlation Euclidian distance metric with 
complete linkage agglomeration method. Hierarchical clustering of genes was done using the z-score values of the 
genes based on Euclidian distance metric with complete linkage agglomeration method.
Statistical analysis. Statistical analysis throughout this study was determined by performing t-test for pair-
wise comparison and the p-values are indicated where appropriate.
Results
Generation of a workflow for identification of new molecular biomarkers. To search for new 
potential molecular biomarkers for AML, we retrieved 5 independent publicly available microarray datasets 
GSE689124 (461 samples), GSE1543425 (251 samples), GSE1320426 (542 samples), GSE115927 (285 samples) and 
GSE2284528 (154 samples) from the Gene Expression Omnibus (GEO) public repository. Firstly, we applied 
our pipeline described in Fig. 1 to the GSE6891 dataset as it encompasses patients with different types of AML 
and every patient within the cohort is annotated with a comprehensive mutational and survival analysis. We 
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developed a computer algorithm to systematically screen every gene probe within the dataset by ranking all 
patients from the lowest to the highest and classifying them into low (0–30% of the expression range) and high 
expressers (70–100%) for each given probe. For each gene, a comparison between the low and high subgroups was 
then made by screening survival data to identify those that have a statistically significant impact on both overall 
and event-free survival, i.e. those demonstrating a p-value lower than 0.05 as calculated by Wilcoxon rank-sum 
test. Upon identification of a positive hit, low and high expresser subgroups were adjusted for age, sex, cytoge-
netic findings, and mutational status and the survival analysis was repeated. After balancing, the list of genes that 















































Figure 1. Flow chart showing the sequential steps for the identification of new molecular biomarkers from 
AML patient expression arrays.
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genes in cancer; the genes that were positive by all those criteria were then surveyed for their influence on global 
gene expression and further validated in the other independent datasets. WBP5, a gene that has recently been 
associated with a variety of cancers and haematological malignancies, passed all criteria and became the main 
subject of this study.
High WBP5 expression is associated with inferior survival in AML patients. In the patient cohort 
described by Verhaak et al.24 we ranked patients according to their WBP5 expression levels and selected the bot-
tom 30% of the whole expression range as low expressers (WBP5low, n = 160) and the top 30% as high expressers 
(WBP5high, n = 72) as indicated in Fig. 2A. We found a large association of high WBP5 levels with poor cytoge-
netic risk, while a large proportion of low expressers belonged to the good risk subgroup (Fig. 2B). Next, we 
compared the survival outcomes for the whole cohort and observed WBP5high patients to be associated with a 
significantly unfavourable overall survival (median OS = 26.56 vs 71.43, p = 0.000001) and event-free survival 
outcome (median EFS = 20.26 vs 58.95, p = 0.00001) (Fig. 2C).
Furthermore, we tested how WBP5 expression could be modulated in different AML subtypes by analysing 
the mutational status of the two subgroups (WBP5high vs WBP5low); this approach demonstrated a correlation of 
high WBP5 expression with adverse cytogenetic findings such as NPM1c and FLT3-ITD, these being found in 
43% vs 15% (p = 0.0000089) and in 40.2% vs 13.7% (p = 0.000013), respectively. Moreover, we found EVI1 to be 
more frequent in the WBP5high group when compared to the WBP5low group (15.27% vs 1.25%, p = 0.000063); 
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Figure 2. High WBP5 expression is associated with unfavourable outcome in patients with AML. (A) Boxplot 
representation of WBP5 expression boundaries for patient samples from the Verhaak et al. dataset (0–30% low 
expression, 70–100% high expression). (B) Boxplot depicting the association of WBP5 expression with risk 
group categorization (poor, intermediate, good and unknown). (C) Kaplan-Meier representation of overall (OS) 
and event-free (EFS) survival for WBP5low and WBP5high AML patients prior to or (D) after balancing for age, 
sex, FAB and cytogenetic findings. The number of patients and the median OS and EFS are indicated in the plot. 
P-value was calculated using Wilcoxon rank-sum test.
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WBP5low patients (11.25% vs 0%, p = 0.0011). Furthermore, we observed the low expressers to be largely associ-
ated with idt(16) (14.37% vs 1.38%, p = 0.0018) and t(8;21) translocation (22% vs 0%, p = 0.0000046), a genetic 
lesion normally associated with good overall survival. No relationship between WBP5 expression and age or sex 
was observed (Table 1).
Considering that NPM1c and FLT3-ITD, often found together, are indicators of bad prognosis while CEBPA 
and t(8;21) predict a more favourable outcome, we postulated that this observation could account for the inferior 
overall and event-free survival observed in the cohort of WBP5high patients. To rule out this possibility, the sub-
groups of low and high expressers were adjusted for age, cytogenetics findings, FAB classification and mutational 
status to avoid a potential bias to a specific driver mutation or subtype.
Surprisingly, survival analysis after balancing revealed that WBP5high patients (n = 27) still displayed infe-
rior overall (median OS = 25.62 vs 79.63, p = 0.00052) and event-free survival (median EFS = 21.67 vs 63.84, 
p = 0.00247) when compared to WBP5low cohort (n = 27), thus suggesting WBP5 expression to be a strong disease 
indicator independently of its association with specific oncogenic mutations. WBP5 was also reported in three 
independent studies to be part of gene expression risk scores that predict adverse outcomes in AML patients;21–23 
to further determine the validity of WBP5 as a potential biomarker and to assess whether WBP5 expression alone 
could predict the inferior outcome determined in those cohorts by the use of those risk panels, we retrieved those 
datasets and performed survival analysis comparing WBP5 low and high expressers. In agreement with the results 




(n = 72) p-value
Molecular abnormalities
IDH1 7 4 0.74231192
IDH2 5 6 0.10035424
NPM1c 24 31 8.95E-06
FLT3-ITD 22 29 1.38E-05
FLT3-TKD 17 7 1
NRAS 22 4 0.07474453
KRAS 4 0 0.31345029
EVI1 2 11 6.37E-05
CEBPA 18 0 0.00112984
Karyotypic abnormalities
+8 10 4 1
−5/7q 6 10 0.00925701
−9q 5 0 0.32772068
11q23 5 3 0.70598866
complex 8 0 0.06052875
NN 50 31 0.10135058
Other 14 9 0.47627351
abn(3q) 0 1 1
failure 1 4 0.03330118
idt(16) 23 1 0.00180154
t(15;17) 1 0 0.1433
t(6;9) 0 1 0.31034483
t(8;21) 32 0 4.68E-06
t(9;22) 1 0 1
FAB classification
M0 8 3 1
M1 25 27 0.00054777
M2 39 20 0.62606826
M4 36 8 0.04664368
M5 39 8 0.0216892
M6 0 1 0.31034483
unknown 3 0 0.55419693
Sex
Male 80 31 0.39421991
Female 80 41 0.39421991
Table 1. Genetic and karyotypic characteristics of the WBP5high and WBP5low patient subgroups. The table 
shows data for the 232 patients from the Verhaak dataset (GSE6891), including the occurrence of common 
karyotypic lesions and molecular aberrations, FAB classification and sex of patients.
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OS = 347.25 vs 691.14, p = 0.01621 and 496.33 vs 1180.73, p = 0.01478) (Fig. S1), thus suggesting that the sole 
expression of WBP5 could serve as a reliable inferior predictor for AML.
WBP5high AML patients display a specific gene expression profile. In order to investigate the molec-
ular profiles associated with different levels of WBP5, we sought to identify similarities and differences between 
the low and high WBP5 expressers by performing differential gene expression analysis between the two groups. 
Differentially expressed genes were considered as those displaying a log fold change (FC) >1 and an adjusted 
p-value < 0.05. These genes were used to hierarchically cluster the patients using Pearson correlation coefficient. 
This analysis showed that most of the high expressers (20 out of 27 patients) formed a discrete cluster with high 
correlation coefficient, with the exception of a subgroup of 5 WBP5high patients that clustered separately and more 
closely with the low WBP5 cohort (Fig. 3A). This could be due to those patients being characterized by a specific 
mutation that was not screened for this analysis.
Next, we studied the identified differential genes that are specifically deregulated in the WBP5high subgroup 
and observed that the high expresser subgroup displayed a distinct gene expression profile, as indicated in the 
heatmap in Fig. 3B.
To validate our observations, we made use of another independent gene expression profiling dataset reported 
by Kohlmann et al.25. For this dataset, which comprises 251 AML patients with normal karyotype, we applied the 
same classification criterion for ranking them into high (n = 23) and low WBP5 expressers (n = 21) and balancing 
for sex, age, FAB and cytogenetic findings. Although this cohort does not encompass patients carrying karyotypic 
lesions, our analysis showed a similar trend, with most of the high expressers forming a defined cluster (Fig. 3C). 
Moreover, those patients again displayed a distinct gene expression profile compared to the low expressers as 
previously seen for the Verhaak dataset, thus strengthening the validity of our observations (Fig. 3D). We further 
confirmed this trend in three other independent cohorts, such as those reported by Valk et al.27, Haferlach et 
al.26 and Taskesen et al.28. Similarly, in the Valk and Taskesen datasets we observed that those patient subgroups 
formed moderate clusters with good correlation coefficients, with the exception of the Haferlach dataset in which, 
despite clustering together, both high and low expressers seemed to form rather smaller sub-clusters (Fig. 2), 
possibly due to the fact that those patients could not be balanced for the lack of information on their cytogenetic 
and mutational statuses.
High WBP5 expression is associated with an elevated HoX cluster gene expression. By per-
forming differential gene expression analysis on all the five independent datasets, within the core of the high 
WBP5 expressers we considered as more highly expressed genes with an average log2 fold change value of at least 
1.5 above and downregulated genes with values at least 1.5 below that of low expressers. Note that in the 15 genes 
showing highest differential expression in most of the cohorts (above 2 log2 FC) we observed several members of 
the HOXA and HOXB gene clusters, among which HOXA9, HOXA5 (with the exception of Kohlmann dataset), 
HOXA10, HOXB2 and HOXB3 (Fig. 4A,B). The full expression data for all the HOXA and HOXB cluster genes are 
provided in Supplementary Fig. 3. Intriguingly, several genes that are known partners of HOXA9, such as MEIS1, 
were also found to be differentially expressed. This has profound implications as those genes play key roles in the 
progression and maintenance of different types of myeloid diseases, and the combination of HOXA9 and MEIS1 
has been shown to be causal for the development of AML30–32.
We also observed a moderate correlation of WBP5 expression with the levels of HOXA7, another gene that was 
reported to influence leukaemia latency and phenotype and is required for efficient immortalization of myeloid 
cells by MLL-ENL fusions33. Analysis of the HOX-Tale partner proteins also revealed higher levels of PBX3 tran-
script in all cohorts, but not that of PBX1 or PBX2.
This analysis also pointed to the higher expression of several other genes normally deregulated in a wide spec-
trum of leukaemias, including genes that act as transcriptional regulators (PRDM16 and NFIX) and a gene that 
influences proliferative advantage and survival (IGFBP2). Moreover, we observed higher expression of a number 
of genes that are part of the FLT3-ITD molecular signature, such as HOXB2, HOXB3, HOXB4, HOXB5, HOXB6, 
CRNDE, CLU, CTSG, COL4A5 and KRT18, among others (Fig. S4)34,35.
We also looked at the expression of genes that have been shown to be directly involved in HOXA-driven leu-
kemogenesis and observed a significant increase in the expression of GATA236, while no difference was observed 
for FLT39,37,38, MYB39,40 or CEBPA41. Intriguingly, we also noted increased expression of FOXC142, although in this 
cohort it failed to reach statistical significance (Fig. 5).
To confirm these observations, we calculated the average mRNA levels of WBP5high and WBP5low patients 
from all the other independent patient gene expression datasets; notably, we observed a gene expression pattern 
similar to the one obtained from the Verhaak cohort, that is, a large elevation of several HOXA and HOXB cluster 
members, such HOXA9, HOXA10 and HOX-TALE partner MEIS1 (Figs. 4A,B, 5 and S3). Several genes which 
influence gene expression, cell growth or that are part of FLT3-ITD signature were confirmed in virtually all 
cohorts as more highly expressed genes, including CPA3, PRDM16, IGFBP2 and CTSG (Fig. S4).
In a recent study by Naivarani et al., WBP5 was included in a 17-probe set signature that is used as predictor 
of long-term prognosis in AML patients characterized by high WT1 levels23. To test this, we probed for this rela-
tionship in our pipeline and observed a strong association between WBP5 and WT1 transcripts in all the dataset 
tested. (Fig. S3).
In summary, these analyses highlight WBP5 as a reliable prognostic and stratification biomarker and the asso-
ciation between high WBP5 expression and the elevation of HOX cluster genes levels.
Discussion
AML is among the most malignant cancers of the blood and due to its heterogeneous nature and complex biolog-
ical behaviours there are currently limited therapeutic approaches.
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The ability to diagnose and prevent myeloid leukaemias is hampered by the lack of quantifiable, reliable, and 
easily measurable biomarkers that correlate with disease progression. Steady improvements in survival rate and 
disease control have been made in the past decades, but despite the efforts aimed at developing new personalized 
and sensitive therapeutic approaches for patient therapy, AML is still associated with high morbidity and mortal-
ity. Recent advances in transcriptomic and epigenomic analysis have been fundamental in providing a compre-
hensive insight into the mechanism of leukaemia progression and in identifying new molecular biomarkers for 

















































































Figure 3. WBP5high and WBP5low subgroups have distinct global gene expression profiles. (A) Hierarchical 
clustering of the Pearson correlation coefficient of mRNA expression showing distinct clusters for high and low 
WBP5 expressers from the Verhaak cohort. The mutational status of every patient is indicated by a colour coded 
graph on the top of the clustering map. A legend indicating each genetic subgroup is placed below the clustering 
map. (B) Heatmap indicating the gene expression profiles of WBP5low and WBP5high subgroups. (C) Hierarchical 
clustering of the Pearson correlation coefficient and (D) heatmap of mRNA values from the WBP5low and 
WBP5high subgroups of the patient cohort reported by Kohlmann et al. The cluster of low and high WBP5 
expressers are indicated with blue and red boxes, respectively.
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In this study, we have developed an unbiased bioinformatic pipeline to screen five independent patient gene 
expression arrays through which we show that higher expression of WBP5 can serve to predict inferior outcome 
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Figure 4. Correlation of high WBP5 expression with HOXA and HOXB clusters gene signatures. (A) Volcano 
plots indicating the most differentially more highly (red dots, above 1.5 log2 FC) and lowly expressed genes 
(blue dots, below −1.5 log2 FC) in the GSE6891 (Verhaak), GSE15434 (Kohlmann), GSE13204 (Haferlach), 
GSE1159 (Valk) and GSE22845 (Taskesen) datasets. The most highly differentially expressed HOXA, HOXB 
and HOX-TALE genes are indicated in each plot. (B) Gene Set Enrichment Analysis (GSEA) plots show 
enrichment of HOXA and HOXB clusters genes ranked using a signal-to-noise metric according to expression 
in WBP5 low versus high expressers.
9Scientific RepoRtS | (2020) 10:3505 | https://doi.org/10.1038/s41598-020-60480-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
WBP5 has been previously proposed as a candidate oncogene in colorectal cancers with microsatellite insta-
bility and its expression is associated with advanced gastric cancers with lymph node metastasis18,19. Moreover, 
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Figure 5. Elevated expression of HOXA, HOXB and HOX partner genes across five different independent gene 
expression datasets. Expression of representative HOXA (HOXA9, HOXA7, HOAX10 and HOXA5) and HOXB 
(HOXB2, HOXB3, HOXB6) cluster genes and HOX partners (MEIS1, PBX1, PBX3 and FOXC1) or downstream 
effectors (MYB, GATA2, FLT3 and CEBPA). Data are represented as boxplots in which high expressers are 
indicated in red and low expressers are indicated in blue. Every plot presents a color-coded boxplot showing 
median and interquartile ranges. The statistical analysis reported indicates p-value adjusted for false discovery 
rates. ***<0.001, **<0.01, *<0.05.
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cell lung cancer patients and to be correlated with shorter survival time and advanced clinical stage. In this latter 
study, the authors showed that WBP5 modulates multidrug resistance both in vitro and in vivo, and that it does so 
by regulating the Hippo pathway20,43. Those studies reported that high expression of WBP5 might be a predictor 
of unfavourable disease progression in many different cancers. Importantly, three independent studies provided 
a strong link between WBP5 expression and adverse clinical outcome in leukaemia21,22. In fact, Metzeler and 
co-workers were the first to report WBP5 as a risk factor by developing an 86-probe set gene expression signa-
ture to predict inferior outcome in patients with CN-AML. In this study, the authors showed patients that are 
characterized by an elevation of those genes displayed a strong association with FLT3-ITD mutation21. This work 
was followed by another study in which Bou Samra et al. proposed WBP5 as part of a further refined prediction 
risk score that consisted of a panel of 22 genes, those being associated with poor prognosis in CN-AML patients. 
Importantly, the authors showed WBP5 to rank first within this prediction panel according to the hazard ratio22. 
In line with those findings, our study demonstrates that high WBP5 expressers have significantly lower overall 
and event-free survival and are associated with an unfavourable prognosis. We found that high WBP5 expressers 
have a higher frequency of FLT3-ITD and NPM1c, which are often found together and are indicators of inferior 
outcome44,45. Conversely, we observed the WBP5low sub-group to correlate with CEBPA and RUNX1-ETO lesions, 
which are generally associated with favourable outcome46. This is consistent with the reports that WBP5 is asso-
ciated with inferior survival in AML patients by displaying the highest hazard ratio and that its high expression 
correlates with advanced clinical stage and poor survival in lung cancers.
In order to gain an insight into the biological influence of aberrant WBP5 expression in AML, we performed 
gene expression analysis in five independent patient expression arrays. Notably, we found that high WBP5 lev-
els correlated with elevated levels of several genes belonging to the HOXA and HOXB clusters; specifically, we 
observed a strong association with HOXA9 and HOXA10 and a moderate correlation with HOXA7. Many studies 
have demonstrated the importance of those genes in regulating the proliferation of haematopoietic cells and how 
their deregulation is paramount in driving the onset of myeloid leukaemias in vivo47–50. Importantly, we also 
observed a strong association of high WBP5 levels with HOXA9 oncogenic partners, among which MEIS1, PBX3 
and FOXC142,51,52. We also observed elevated expression of a number of cancer-associated genes that have been 
reported to influence the proliferative advantage and the survival of leukaemic cells and genes that were reported 
to be part of the FLT3-ITD molecular signature, such as CRNDE, CLU, CTSG, IGFBP2, CPA3 and PRDM1634,35. 
Notably, we also observed a strong association of WBP5 with WT1, in agreement with previous reports. Our 
work suggests that a major mechanism of WBP5 influencing leukaemia behaviour might directly or indirectly 
act through regulating these genes. To date, WBP5 has been considered within risk prediction signatures to infer 
on clinical outcome but the importance of the sole WBP5 expression as a reliable biomarker has not been inves-
tigated. We did so by performing survival analysis comparing low and high WBP5 expressers in the cohort of 
patients from which those gene expression prognostic signatures have been determined and observed that WBP5 
alone was able to predict the same inferior clinical outcome in those patients. As such, our data suggest that it 
would be fruitful to perform a more elaborate study to further validate the importance of those findings in vitro 
and in vivo.
Taken together, our bioinformatic approach shows that WBP5 expression is a reliable and powerful indicator 
of inferior outcome for AML and that it may be a candidate target for developing new therapeutic approaches.
code availability
The full code to reproduce the data presented in this manuscript is available at https://github.com/doncarlos999/
WBP5_analysis.
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